Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive save search
New Research Confirms Positive Impact of OneMain's BUILD Credit Education
Published: 2024-03-07 (Crawled : 23:00) - prnewswire.com
OMF | $47.44 1.3% 0.0% 1.2M
|
Finance
|
| O: 0.66%
H: 0.65%
C: -1.0%
positive research education impact
Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024
Published: 2024-03-07 (Crawled : 15:30) - globenewswire.com
VAXX | $0.4476 0.34% 0.34% 440K
|
|
| O: -1.42%
H: 37.63%
C: 11.15%
disease positive parkinson’s trial
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsCompany maintains solid cash position of $158.9 million
Published: 2024-03-07 (Crawled : 15:30) - biospace.com/
RAPT | $8.13 -4.8% -5.04% 540K
|
Health Technology
|
| O: 0.66%
H: 4.57%
C: 0.87%
year million therapeutics financial
Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4
Published: 2024-03-07 (Crawled : 14:30) - biospace.com/
APVO 3 d | $0.761 -2.81% -2.89% 550K
|
Health Technology
|
| O: 19.53%
H: 41.18%
C: -13.73%
apv-527 alg.apv-527 positive bioscience tumor therapeutics study
Proof Positive & Members of its Nationwide Autism Wellbeing Alliance Celebrate Global Commitment to the Autism Community on International Day of Happiness
Published: 2024-03-07 (Crawled : 12:30) - prnewswire.com
FNCTF | $11.128 -20.84% 580
|
Communications
|
| O: 0.79%
H: 0.78%
C: 0.78%
day positive international global nationwide
Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US
Published: 2024-03-07 (Crawled : 11:00) - globenewswire.com
IMRN | $2.37 -8.49% -9.28% 51K
|
Health Technology
|
| O: 104.23%
H: 76.85%
C: 35.01%
travelan positive trials results
Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin Disorders
Published: 2024-03-06 (Crawled : 15:30) - globenewswire.com
PHIO | $0.6656 -3.68% 20K
|
Health Technology
|
| O: 5.81%
H: 26.37%
C: 0.77%
patent granted disorders pharmaceuticals skin
Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve(R) Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting
Published: 2024-03-06 (Crawled : 14:30) - biospace.com/
NVNO | $4.805 -2.34% -2.39% 64K
|
Manufacturing
|
| O: 2.96%
H: 3.48%
C: -9.7%
enous2024 positive topline meeting trial today
Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve® Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting
Published: 2024-03-06 (Crawled : 14:30) - hancockjaffe.com
NVNO | $4.805 -2.34% -2.39% 64K
|
Manufacturing
|
| O: 2.96%
H: 3.48%
C: -9.7%
enous2024 venovalve positive topline meeting trial today
Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia
Published: 2024-03-06 (Crawled : 13:30) - globenewswire.com
NXL | $1.4 -29.29% -41.43% 750K
|
|
| O: -1.61%
H: 95.85%
C: 52.0%
device positive technology results study
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
Published: 2024-03-06 (Crawled : 13:30) - prnewswire.com
GNPX | $2.29 -2.55% -2.62% 20K
|
Health Technology
|
| O: 24.27%
H: 5.66%
C: -14.45%
reqorsa lung positive treatment system preclinical meeting therapy
Alibaba Releases Report on Cross-Border Trade's Positive Impact on the U.S. Economy
Published: 2024-03-06 (Crawled : 11:00) - prnewswire.com
BABA | $69.61 -1.43% 0.0% 17M
|
Retail Trade
|
| O: 2.96%
H: 0.7%
C: -0.66%
report positive impact
Virbac to take a leading position in Japan through the acquisition of Sasaeah
Published: 2024-03-06 (Crawled : 08:00) - globenewswire.com
ORXCF | $20.68 -11.43% 43
|
Finance
| Email alert
Add to watchlist
japan acquisition
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
Published: 2024-03-05 (Crawled : 16:00) - biospace.com/
SNY | $45.81 -0.93% -0.94% 1.4M
|
Health Technology
|
| O: 1.17%
H: 0.0%
C: 0.0%
ALNY | $146.86 -0.57% -0.57% 350K
|
Health Technology
|
| O: -0.73%
H: 1.52%
C: 0.5%
positive blood care topline results study
N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study
Published: 2024-03-05 (Crawled : 14:30) - immunitybio.com
IBRX | $4.94 -5.73% -6.07% 2.9M
|
Manufacturing
|
| O: -1.38%
H: 6.6%
C: -3.6%
cure natural positive hiv potential study
FSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum
Published: 2024-03-05 (Crawled : 14:00) - biospace.com/
HUGE | $0.6167 1.22% 29K
|
Process Industries
|
| O: -13.48%
H: 15.52%
C: 12.05%
pharma positive sclerosis treatment research results lucid-21-302 study
CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China
Published: 2024-03-05 (Crawled : 12:00) - prnewswire.com
CASI | $2.5 0.0% 30K
|
Health Technology
|
| O: 21.93%
H: 10.65%
C: -8.71%
bi-1206 report positive treatment pharmaceuticals china
REGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE® TRIAL
Published: 2024-03-05 (Crawled : 12:00) - prnewswire.com
RGNX | $17.49 -2.94% -3.03% 300K
|
Health Technology
|
| O: 32.77%
H: 1.55%
C: -13.22%
duchenne positive trial
Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program
Published: 2024-03-05 (Crawled : 12:00) - globenewswire.com
MNPR | $0.729 -3.44% -3.57% 180K
|
Health Technology
|
| O: 5.04%
H: 15.38%
C: 1.92%
mnpr-101 positive preclinical program
Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of Schedule with Half-Life of Approximately 75 Days
Published: 2024-03-05 (Crawled : 11:00) - globenewswire.com
APGE | $50.745 -4.38% -4.58% 350K
|
|
| O: 43.53%
H: 9.18%
C: -1.02%
apg777 antibody dermatitis positive treatment trial results
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
WISA 4 | $6.06 246.29% 71.12% 200M
|
Electronic Technology
VIAO | $0.265 -13.96% 35.85% 960K
|
Electronic Technology
JAGX | $0.178 49.83% 33.26% 600M
|
Health Technology
SXTC | $1.68 43.59% 30.36% 34M
|
Health Technology
DYNT | $0.531 43.36% 30.24% 22M
|
Health Technology
KA | $0.4796 41.06% 29.11% 5.3M
|
Manufacturing
PALI | $5.86 40.87% 29.01% 29M
|
Manufacturing
CLNN | $0.319 -3.74% 28.75% 6.3M
|
BSGM | $1.52 38.18% 27.63% 3.3M
|
Health Technology
MCBC | $13.67 37.66% 27.36% 2.2M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.